← ANALYST RATINGS · TIPRANKS
Roivant Sciences (ROIV): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy1 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $47.43, the highest $55.00, the lowest $40.00. The average is +41.5% from the last price of $33.53.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 17.10.26on TipRanks 15:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $36.00 → $37.00+2.8% | Hold | +10.3% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $36.00 → $37.00+2.8% | Hold | +10.3% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $39.00 → $38.00−2.6% | Buy | +13.3% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $37.00 → $36.00−2.7% | Hold | +7.4% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $38.00 → $37.00−2.6% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $38.00 → $37.00−2.6% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $38.00 → $37.00−2.6% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $38.00 → $37.00−2.6% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $40.00 → $39.00−2.5% | Buy | +16.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $38.00 → $37.00−2.6% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $46.00 | Buy | +37.2% | Assigned | 12.10.26on TipRanks 17:58 | −3.6%next day +1.9% | ↗ |
| Chi Meng Fong★★★★★★★★★★#8521 · hits 44% · avg +0.2% | Bank of America Securities | $41.00 | Hold | +22.3% | Reiterated | 12.10.26on TipRanks 08:45 | −2.3%next day −3.6% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | — | Hold | — | Downgrade | 12.10.26on TipRanks 07:00 | −2.3%next day −3.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $37.00 → $38.00+2.7% | Hold | +13.3% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $36.00 → $38.00+5.6% | Hold | +13.3% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $38.00+2.7% | Hold | +13.3% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $37.00 → $38.00+2.7% | Hold | +13.3% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $38.00 → $40.00+5.3% | Buy | +19.3% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $36.00 → $38.00+5.6% | Hold | +13.3% | Reiterated | 11.10.26on TipRanks 08:05 | — | |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $41.00 | Buy | +22.3% | Reiterated | 25.09.26on TipRanks Sep 26 12:55 | −1.5%next day +4.0% · 5 days 0.0% | ↗ |
| Chi Meng Fong★★★★★★★★★★#8521 · hits 44% · avg +0.2% | Bank of America Securities | $37.50 → $41.00+9.3% | Hold | +22.3% | Reiterated | 22.09.26on TipRanks Sep 23 06:50 | −2.0%next day −2.9% · 5 days −3.3% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Buy | — | Reiterated | 17.09.26on TipRanks Sep 18 04:45 | −0.1%next day −0.7% · 5 days −10.5% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $51.00 | Buy | +52.1% | Initiated | 17.09.26on TipRanks Sep 16 16:20 | −0.1%next day −0.7% · 5 days −10.5% | ↗ |
| Unknown Analyst | Leerink Partners | $42.00 → $52.00+23.8% | Buy | +55.1% | Reiterated | 16.09.26on TipRanks 16:20 | −0.1%next day −0.7% · 5 days −10.5% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $50.00 → $55.00+10.0% | Buy | +64.0% | Assigned | 09.09.26on TipRanks Sep 8 18:30 | +1.3%next day −1.5% · 5 days −4.3% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $47.00 | Buy | +40.2% | Assigned | 09.09.26on TipRanks Sep 8 12:40 | +19.3%next day +1.3% · 5 days −3.7% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $42.00 → $46.00+9.5% | Buy | +37.2% | Reiterated | 08.09.26on TipRanks Sep 9 07:30 | +19.3%next day +1.3% · 5 days −3.7% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $42.00 → $52.00+23.8% | Buy | +55.1% | Reiterated | 08.09.26on TipRanks 11:05 | +19.3%next day +1.3% · 5 days −3.7% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $40.00 | Buy | +19.3% | Reiterated | 28.08.26on TipRanks 07:36 | −7.4%next day +0.1% · 5 days +0.5% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $42.00 → $46.00+9.5% | Buy | +37.2% | Reiterated | 10.08.26on TipRanks 06:55 | −1.5%next day −1.2% · 5 days +1.3% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $38.00 → $41.00+7.9% | Buy | +22.3% | Reiterated | 15.04.26on TipRanks 07:50 | +0.1%next day −0.9% · 5 days −2.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Roivant Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $47.10 at a price of $35.44 (+32.9%); now: $47.10 at $33.53 (+40.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 14 | 10 | 7 | 11 | 18 | 17 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q2 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.37 (from $-0.59 to $-0.19). Last quarter: $-0.34.
Sales
Next quarter’s sales estimate — $4M (from $0M to $8M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Roivant Sciences
- CEO: Matthew Gline
- Employees: 721
- 50 Broadway, London, GL, SW1H 0DB, GB
- roivant.com
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Data from the stock’s TipRanks forecast page, read 43 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗